FDA Inspection
GlaxoSmithKline Biologicals SAGlaxoSmithKline Biologicals SA – FDA Inspection, Feb 27, 2026
Record Details
This FDA Inspection record concerns GlaxoSmithKline Biologicals SA, with an inspection on February 27, 2026, issued by the Office of Inspections and Investigations, covering biologics.
View Company Profile
ID · a73f4473-48f2-4d60-ada1-1284eeb61f46
Inspection Facts
- Inspection number
- 1305486
- FDA center
- Biologics
- Project area
- Vaccine, Allergenic, and Live Biotherapeutic Products
- Outcome
- Form 483 issued
FDA Citations
6- 21 CFR 211.100(a)Absence of Written Procedures
- 21 CFR 211.100(b)Procedure Deviations Recorded and Justified
- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.113(b)Validation lacking for sterile drug products
- 21 CFR 211.42(c)(10)(iv)Environmental Monitoring System
- 21 CFR 211.68(b)input/output verification
Full citation text and observation details available on the Dashboard.
Other FDA inspections of GlaxoSmithKline Biologicals SA
2| Date | Classification | Office | Project area |
|---|---|---|---|
| June 23, 2023 | Not classified | Office of Inspections and Investigations | |
| June 24, 2019 | Not classified | Office of Inspections and Investigations |
Other documents for GlaxoSmithKline Biologicals SA
- FDA Inspection 1214970 - 2023-06-23
- FDA Inspection 1099401 - 2019-06-24
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.